About the Trial

ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330

Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects with Non-Proliferative Diabetic Retinopathy and Mild Proliferative Diabetic Retinopathy